Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly

被引:131
作者
Stomrud, Erik [1 ]
Hansson, Oskar
Blennow, Kaj
Minthon, Lennart
Londos, Elisabet
机构
[1] Lund Univ, Malmo Univ Hosp, Dept Clin Sci Malmo, Clin Memory Res Unit, SE-20502 Malmo, Sweden
[2] Univ Gothenburg, Sahlgrenska Univ Hosp, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Molndal, Sweden
关键词
Alzheimer disease; early diagnosis; dementia; mild cognitive impairment; cerebrospinal fluid biomarker; Tau protein; beta-amyloid; 42;
D O I
10.1159/000105017
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive decline in healthy, elderly individuals as they have been shown to do in cognitively impaired patient samples. Methods: In this study, 57 controls were tested for CSF biomarkers at baseline and then cognitively followed over 3 years. Results: Low levels of baseline beta-amyloid 1 - 42 (A beta 42) were associated with development of subjective memory impairment affecting quality of life (memQoL), with a worse Mini Mental Status Examination score and with inability to live in regular housing at follow-up ( p < 0.05). The combination of baseline A beta 42 and phosphorylated tau (P-tau) was found to predict development of pathological memQoL with a sensitivity of 71.4% and a specificity of 75.7 (< 0.01). Conclusion: Low A beta 42 and combined A beta 42 and P-tau predicted subjective cognitive decline in healthy individuals. In summary, this study shows that already in the clinically normal population Alzheimer-disease-related biological signs might be detectable. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:118 / 124
页数:7
相关论文
共 37 条
[21]   Assessing quality of life in older adults with cognitive impairment [J].
Logsdon, RG ;
Gibbons, LE ;
McCurry, SM ;
Teri, L .
PSYCHOSOMATIC MEDICINE, 2002, 64 (03) :510-519
[22]   Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease [J].
Maruyama, M ;
Higuchi, M ;
Takaki, Y ;
Matsuba, Y ;
Tanji, H ;
Nemoto, M ;
Tomita, N ;
Matsui, T ;
Iwata, N ;
Mizukami, H ;
Muramatsu, SI ;
Ozawa, K ;
Saido, TC ;
Arai, H ;
Sasaki, H .
ANNALS OF NEUROLOGY, 2005, 57 (06) :832-842
[23]  
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
[24]  
Meek PD, 1998, PHARMACOTHERAPY, V18, P68
[25]   Advances in the early detection of Alzheimer's disease [J].
Nestor, PJ ;
Scheltens, P ;
Hodges, JR .
NATURE MEDICINE, 2004, 10 (07) :S34-S41
[26]   Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology [J].
Olsson, A ;
Vanderstichele, H ;
Andreasen, N ;
De Meyer, G ;
Wallin, A ;
Holmberg, B ;
Rosengren, L ;
Vanmechelen, E ;
Blennow, K .
CLINICAL CHEMISTRY, 2005, 51 (02) :336-345
[27]   Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment [J].
Pesaresi, Marzia ;
Lovati, Carlo ;
Bertora, Pierluigi ;
Mailland, Enrico ;
Galimberti, Daniela ;
Scarpini, Elio ;
Quadri, Pierluigi ;
Forloni, Gianluigi ;
Mariani, Claudio .
NEUROBIOLOGY OF AGING, 2006, 27 (06) :904-905
[28]   Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Petersen, RC ;
Stevens, JC ;
Ganguli, M ;
Tangalos, EG ;
Cummings, JL ;
DeKosky, ST .
NEUROLOGY, 2001, 56 (09) :1133-1142
[29]  
Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO
[30]  
2-X